Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy underperformed its benchmark, the Russell Midcap® Growth Index, in the third quarter of 2025, which increased approximately 3%.  In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Brown Advisory Mid-Cap Growth Strategy highlighted stocks such as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based on ribonucleic acid interference. The one-month return of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was -9.24%, and its shares gained 61.36% of their value over the last 52 weeks. On December 18, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock closed at $396.04 per share, with a market capitalization of $52.322 billion.

Brown Advisory Mid-Cap Growth Strategy stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its third quarter 2025 investor letter:

"Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Develops and commercializes therapeutics based on RNA interference. Alnylam Pharmaceuticals (ALNY) reported strong second quarter results driven by a faster-than-consensus expected launch of Amvuttra in the newly approved cardiomyopathy indication."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 72 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the third quarter, which was 58 in the previous quarter. In the third quarter of 2025, the product revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 103% year-over-year to $851 million. While we acknowledge the potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and shared Carillon Eagle Mid Cap Growth Fund's views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.